Harbor Capital Advisors Inc. bought a new position in shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR – Get Rating) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 83,619 shares of the company’s stock, valued at approximately $390,000.
Other large investors have also added to or reduced their stakes in the company. Moors & Cabot Inc. purchased a new position in shares of TCR2 Therapeutics during the third quarter valued at $25,000. Macquarie Group Ltd. purchased a new position in shares of TCR2 Therapeutics during the third quarter valued at $30,000. BNP Paribas Arbitrage SA increased its stake in shares of TCR2 Therapeutics by 126.6% during the third quarter. BNP Paribas Arbitrage SA now owns 7,831 shares of the company’s stock valued at $67,000 after buying an additional 4,375 shares during the period. Marquette Asset Management LLC purchased a new position in shares of TCR2 Therapeutics during the fourth quarter valued at $93,000. Finally, Point72 Hong Kong Ltd increased its stake in shares of TCR2 Therapeutics by 557.3% during the third quarter. Point72 Hong Kong Ltd now owns 11,023 shares of the company’s stock valued at $94,000 after buying an additional 9,346 shares during the period. Institutional investors and hedge funds own 80.16% of the company’s stock.
NASDAQ TCRR traded up $0.11 during trading on Tuesday, hitting $2.49. The company’s stock had a trading volume of 10,487 shares, compared to its average volume of 623,761. The company has a market cap of $95.98 million, a PE ratio of -0.90 and a beta of 2.26. The business’s 50 day simple moving average is $2.71 and its 200-day simple moving average is $4.49. TCR2 Therapeutics Inc. has a fifty-two week low of $2.33 and a fifty-two week high of $25.22.
Several research firms have issued reports on TCRR. Piper Sandler cut their target price on TCR2 Therapeutics from $26.00 to $23.00 in a research note on Tuesday, March 22nd. Zacks Investment Research lowered TCR2 Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 18th. HC Wainwright cut their target price on TCR2 Therapeutics from $25.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, January 13th. Finally, The Goldman Sachs Group lowered TCR2 Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $28.00 to $5.00 in a research note on Wednesday, January 19th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $17.39.
TCR2 Therapeutics Company Profile (Get Rating)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.